Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides.
Lindsley
Craig W
CW
Department of Medicinal Chemistry, Technology Enabled Synthesis Group, Merck Research Laboratories, P.O. Box 4, West Point, PA 19486, USA. craig_lindsley@merck.com
Zhao
Zhijian
Z
Leister
William H
WH
O'Brien
Julie
J
Lemaire
Wei
W
Williams
David L
DL
Chen
Tsing-Bau
TB
Chang
Raymond S L
RS
Burno
Maryann
M
Jacobson
Marlene A
MA
Sur
Cyrille
C
Kinney
Gene G
GG
Pettibone
Douglas J
DJ
Tiller
Philip R
PR
Smith
Sheri
S
Tsou
Nancy N
NN
Duggan
Mark E
ME
Conn
P Jeffrey
PJ
Hartman
George D
GD
D000818:Animals; D014150:Antipsychotic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D001549:Benzamides / Q000737:chemistry*; D015195:Drug Design; D050487:Glycine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors*; D051379:Mice; D008811:Mice, Inbred DBA; D051381:Rats; D012559:Schizophrenia / Q000188:drug therapy; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000737:chemistry*
D014150:Antipsychotic Agents; D001549:Benzamides; D050487:Glycine Plasma Membrane Transport Proteins; D013449:Sulfonamides